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Background: Previous studies have shown that acupuncture can alleviate postmenopausal symptoms, such as hot
flashes, but few studies have assessed symptoms during the menopausal transition (MT) period. Thus, the effect of
acupuncture upon MT symptoms is unclear. We designed a large-scale trial aimed at evaluating the efficacy of
electroacupuncture for MT symptoms compared with sham electroacupuncture and at observing the safety of
electroacupuncture.
Methods/design: In this multicenter randomized controlled trial, 360 women will be randomized to either an
electroacupuncture group or a sham electroacupuncture group. During the 8-week-long treatment, a menopause
rating scale, average 24-hour hot flash score, Menopause-Specific Quality of Life Questionnaire score, and level of
female hormones will be observed. Follow-ups at the 20th and 32nd week will be made.
Discussion: Though there is no completely inert placebo acupuncture and blinding is difficult in acupuncture trials,
the placebo effect of EA can still be partially excluded in this study. For the placebo control, we use non-points
and a tailor-made sham needle. This needle is different from a retractable needle, which is usually used for sham
acupuncture. The needle in this trial is more simply constructed and more acceptable to Chinese people. We
expect to evaluate the efficacy of electroacupuncture for MT symptoms and clarify its effect on these symptoms.
Trial registration: ClinicalTrials.gov Identifier: NCT01849172 (Date of registration: 05/05/2013).
Keywords: Electroacupuncture, Menopausal transition, Multicenter randomized controlled trial, SafetyBackground
The menopausal transition (MT) period refers to the time
from the commencement of variations in menstrual cycle
length and a monotropic rise in follicle-stimulating hor-
mone to the final menstrual period. It is further divided
into two phases: the ‘early MT’ in which cycle lengths vary
by more than 7 days from the typical length for the indi-
vidual woman and the ‘late MT’, characterized by at least
two skipped cycles and at least one period of amenorrhea
exceeding 60 days [1-4]. Different symptoms appear dur-
ing different phases of the MT period. Hot flashes are the
most frequent symptom and the prevalence of flashes can* Correspondence: liuby@mail.cintcm.ac.cn
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Other symptoms include night sweats, sleep disturbances,
vaginal dryness, urinary incontinence, weight gain, fatigue,
irritability, and anxiety. Studies find that most women ex-
perience at least one or more of these symptoms as they
transit through the postmenopausal stage of life [7].
Hormone therapy (HT) is the recommended drug for
women with symptoms related to postmenopause [8]. Be-
cause of its long-term risks, HT is no longer prescribed as
preventive therapy, but rather for managing menopausal
symptoms [9]. Treatment of the perimenopausal woman
represents a greater challenge than the menopausal
woman because of unpredictable and unstable ovarian
function [10]. A study of women’s decision making during
the MT has shown that participants believe thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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product rather than HT [11].
As part of complementary and alternative medicine,
acupuncture has been used in many clinical trials in re-
cent years. Existing studies have shown that acupuncture
can alleviate postmenopausal-related symptoms, but we
were unable to find many trials on the MT period. A re-
view of acupuncture for treating menopausal hot flashes
included six randomized controlled trials (RCTs), which
compared acupuncture with sham acupuncture, and they
concluded that sham-controlled RCTs failed to show any
specific effects of acupuncture for control of menopausal
hot flashes [12]. Two trials conducted separately in the
United States and South Korea on perimenopausal and
postmenopausal women showed acupuncture was benefi-
cial for hot flashes, though it was not more effective than
sham acupuncture [13,14]. The limitations of the above
two trials were that both trials had small samples (n = 103
and n = 175, respectively), they included both perimeno-
pausal and postmenopausal women, treatment sessions
were insufficient (one trial had 10 sessions in 5 weeks and
the other 12 sessions in 4 weeks), and follow-up periods
were short-term (7 weeks and 4 weeks). Another trial con-
ducted in South Korea reached a similar conclusion that
acupuncture failed to show significant effects on hot flash
scores compared with sham acupuncture, but it showed
partial benefits for hot flash severity [15]. Several trials
[16-20] conducted in China demonstrated that electroacu-
puncture (EA) could reduce the Kupperman Index,
follicle-stimulating hormone (FSH), and luteinizing hor-
mone (LH), and increase estradiol (E2), but none of these
trials used a sham control or had follow-up. In sum, most
trials so far have focused on hot flashes in postmenopausal
women and no significant differences were found between
acupuncture and sham control. The few trials on MT-
related symptoms showed that there was not enough evi-
dence to support acupuncture’s efficacy for MT [21].
We have finished a phase I trial (unpublished), which
was a single-blinded (patients blinded) RCT study; 16
women with MT-related symptoms were observed. They
were randomized into an EA group (n = 8) and a sham EA
group (n = 8). After 8 weeks, the reduction in the meno-
pause rating scale (MRS) was 6.5 ± 9.96 (20.54 ± 14.82 at
baseline and 14.00 ± 4.47 after treatment) and 2.00 ± 7.39
(21.50 ± 13.03 at baseline and 19.50 ± 7.85 after treatment)
for the EA and sham EA groups, respectively. There was a
significant difference between the two groups and the re-
sults suggested EA could be beneficial for MT symptoms
and have a therapeutic effect.
This protocol is designed for the phase II trial. It is a
multi-center randomized placebo controlled trial. It will
compare EA with sham EA for symptoms during MT.
The primary objective is to evaluate the therapeutic effect
of EA for MT symptoms, and to partially exclude theplacebo effect. The second objective is to evaluate EA’s
safety and any positive effect on the sexual hormone levels
(FSH, LH, FSH/LH, and E2) in MT.Methods/design
This will be a prospective RCT conducted over 2 years
(from June 2013–May 2015) and at 12 hospitals in China
(Guang’anmen Hospital; The First Hospital Affiliated to
Anhui University of Chinese Medicine; Guangdong Provin-
cial Hospital of Traditional Chinese Medicine (TCM);
Hubei Province Hospital of TCM; The First Hospital of
Hunan University of Chinese Medicine; Hengyang Hospital
of Hunan University of Chinese Medicine; Affiliated Hos-
pital of Shandong University of TCM; Integrated TCM and
Western Medicine of Shanxi University of TCM; Shanxi
Province Hospital of TCM; Yueyang Hospital of Shanghai
University of TCM; TCM Hospital of Yantai; and 3rd
Hospital of Zhejiang Chinese Medical University).
Participants experiencing MT will be recruited from the
12 centers by use of advertisements in newspapers, televi-
sion, websites, and posters. Participants will be sent to a
gynecologist who will make the diagnosis. A 1-week base-
line assessment will include MRS, Menopause-Specific
Quality of Life Questionnaire score (MENQOL), average
24-h hot flash score, and hormone levels (FSH, LH, FSH/
LH, and E2, examined at days 2 to 4 of the menstrual
period or any day for participants in menopause). Eligible
participants will be randomized after their informed con-
sents are obtained. Central randomization will be per-
formed by the Clinical Evaluation Center of the China
Academy of Chinese Medical Sciences in Beijing. Stratified
block randomization will be made according to the hos-
pital and a block size of six will be used. A random num-
ber will be immediately received by the acupuncturist by
phone or online after the informed consent is signed. All
of the participants, statisticians, outcome assessors, and
the gynecologists are blinded to the allocation, except for
the acupuncturists. The flowchart of the trial is presented
in Figure 1.Ethics
The trial will be conducted in accordance with the princi-
ples of the Declaration of Helsinki and has been approved
by the review boards and ethics committees of the 12
centers (Ethics approval numbers: 2013EC061-01; 2013
AH-015; B2013-00084-01; HBZY2013-C025-01; HN-LL-
KY-2013-004-01; 2013EC002; 2013020-KY; 2013EC061-01
(20130515); 20130419; 20130620; 2013001; ZSLL-KY-2013-
001) (Additional file 1).Participants
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Figure 1 The flow chart.
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Participants conforming to all the following conditions
will be included: i) cycle irregularity (period occurring
7 days earlier or later) in the past 12 months (early
MT) and the last menstruation being at least 2 months
previously, but no longer than 11 months previously in
the past 12 months (late MT); ii) MT symptoms such
as hot flashes, sweating, sleep disturbance, migraine,
anxiety, vaginal dryness, and sexual problems; iii) aged
40 to 55 years old; iv) negative pregnancy test; and v)participation is voluntarily and the informed consent
signed.
Exclusion criteria
Participants with the following conditions will be ex-
cluded: i) regular cycles during the past 3 months be-
fore enrollment; ii) use of estrogen, serotonin-reuptake
inhibitors, soybean isoflavone, progestin, vitamin E, or
black sesame in the past 4 weeks; iii) presence of ovar-
ian cyst, uterine myoma (diameter ≥4 cm), or after
Liu et al. Trials 2014, 15:242 Page 4 of 7
http://www.trialsjournal.com/content/15/1/242hysterectomy/ovariectomy; iv) participants with a radio-
chemotherapy history or undergoing radiochemotherapy;
v) cryptogenic vaginal bleeding; vi) coagulation disorder or
use of anticoagulants like warfarin and heparin sodium; vii)
existing skin diseases like eczema or psoriasis; viii) severe
hepatic/renal insufficiency; ix) insufficiently controlled
hypertension, diabetes, or thyroid diseases; x) existing
diabetic neuropathy, malignant tumor, and psychiatric
disorders; xi) desire to become pregnant or pregnant or
breast-feeding; xii) regular use of sedatives or anxio-
lytics; xiii) smoking or heavy alcohol intake; xiv)
mandatory indication for HT (e.g., postsurgical meno-
pause or active osteoporosis); and xv) presence of a car-
diac pacemaker or artificial joint.
Interventions
The regimen will be based on a Chinese literature review
from the previous 10 years, our phase I trial and special-
ist’s consensus. Acupuncturists with over 2 years working
experience and academic credentials above an under-
graduate degree in each hospital will be trained with the
protocol before the start of the trial. One session will be
given every other day, three sessions per week (24 sessions
in all), and each session will last for 30 minutes. A re-
served time is made for treatment to prevent participants
from communicating with each other.
Electroacupuncture group
Acupoints RN4, EX-CA1, ST25, and SP6 on double sides
are used. Stick adhesive pads (Figure 2) are placed at all
points. For ST25, EX-CA1, and RN4, the needle will be
inserted (75 mm) vertically through the pads and quickly
through the skin, and then slowly and vertically penetrate
through the layer of fatty tissue, up into the muscles of the
abdominal wall (until the moment of resistance is sensed
on the tip of the needle and the participant feels a sting).
For RN4, the needle will be manipulated slightly with an
even lifting, thrusting, and twisting method, repeated
three times. The needle will be inserted (40 mm) vertically
at SP6 to a depth of 1 cun. The needle will be manipulated
slightly with an even lifting, thrusting, and twisting
method repeated three times to reach de-qi. The electric
stimulator will be put on the EX-CA1 and ST25 points
with a dilatational wave, 10/50 Hz, 0.1 to 1.0 mA. TheFigure 2 Adhesive pad. The adhesive pad used in the trial. The
bottom face is adhesive and sticks to the skin.current intensity will be increased until the abdomen
shivers. The needles are left for 30 minutes and the same
manipulation methods for RN4 and SP6 will be given
every 10 minutes (three times in all) (Figure 3).Sham-electroacupuncture group
Non-points proximate to RN4 (P1), EX-CA1 (P2), ST25
(P3), and SP6 (P4) on double sides will be used. P1 and P3
are at the sites 1 cun (outward in horizontal direction)
proximate to RN4 and ST25, respectively. P2 is 2 cun
(outward in horizontal direction) proximate to EX-CA1.
P4 is at the middle site of the spleen meridian and the kid-
ney meridian (backward in the horizontal direction prox-
imate to SP6). Adhesive pads will be applied to all points.
Blunt needles will be inserted but not to pierce the skin.
The needle will be manipulated slightly with an even
lifting, thrusting, and twisting method repeated three
times for each point. The sham electric stimulator will be
put on P2 and P3 with the same parameters as the EA
group, but without current intensity. The needles will be
left for 30 minutes and the same manipulation methods
for all points will be given every 10 minutes. Every point
will be checked after treatment to make sure there is no
needle hole in the skin.
For participants undergoing bleeding, treatment will be
provided. However, for individual participants who do not
want needling during their periods, the treatment and out-
come assessment will be postponed.
Other MT-relevant treatments will not be allowed
throughout the trial. For any use of other treatments, in-
formation should be recorded on the case report form in
detail. The proportion of participants using other MT-
relevant treatment will be compared between groups.Figure 3 Some points used in the trial.
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The primary outcome is the change in the MRS compared
with baseline at the 8th week (the primary time frame)
and at the 4th, 20th, and 32nd week (the secondary time
frame). The secondary outcomes include changes in the
average 24-h hot flash score [22] (1-week sum score di-
vided by 7, evaluated at the 4th, 8th, 20th, and 32nd week),
MENQOL (at the 4th, 8th, 20th, and 32nd week), and
FSH, LH, FSH/LH, and E2 (examined at days 2 to 4 of the
menstrual period or for participants in menopause, at the
end of the 8th week) compared with baseline.
Safety evaluation and blinding assessment
Safety evaluation will be based on events including faint-
ing, severe pain, hematoma, local infection, and other feel-
ings of discomfort. Any adverse event will be recorded in
detail.
To assess whether the sham control is successful, two
centers will be randomly chosen to report the EA data by
means of a blinded questionnaire (Figure 4). All partici-
pants from the two centers will be asked to complete the
questionnaire within 5 minutes after any treatment ses-
sion in the 4th and 8th week. The percentage of partici-
pants reporting EA data will be compared between the
two groups and success of the blinding will be analyzed.
Sample size and statistical analysis
According to our pilot trial, the reduction of MRS after
an 8-week treatment was 6.5 ± 9.96 (mean ± standardFigure 4 Blinding questionnaire.deviation) and 2.00 ± 7.39 for the acupuncture and sham
acupuncture groups, respectively. Considering it is a
multicenter trial, we expanded the standard deviation to
1.5 times to enhance the reliability of the study. As a
minimum 5-point reduction in MRS is considered ef-
fective [23], to detect a reduction of 5 points with a
two-sided 5% significance level and a power of 95%,
180 participants will be needed for each group (1:1 ra-
tio) allowing for a 20% dropout rate.
Data from the 12 hospitals will be pooled and the
Clinical Evaluation Center of China Academy of Chinese
Medical Sciences in Beijing will conduct a statistical ana-
lysis. According to the principle of intention-to-treat
(ITT), all randomized participants will be analyzed. All
statistical analyses will be two-sided tests and the level
of significance will be established at 0.05. SAS 9.1.3 (SAS
Institute, Cary, NC, USA) and SPSS Ver.13.0 (SPSS Inc.,
Chicago, IL, USA) software will be used. Continuous
data will be represented by the mean, standard deviation,
median, minimum value, and maximum value; categor-
ical data will be represented by percentages. For com-
parison with the baseline, a t-test or nonparametric test
will be used for continuous data, and nonparametric
tests for categorical data. For comparison of two inde-
pendent samples a t-test or nonparametric test will be
used for continuous data, and a χ2 test or the Fisher
exact test will be used for categorical data. The multiple
imputation method will be used to handle the missing
data. The statistical methods are as follows:
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distribution of both groups in every center will be
described. The total drop-out rate and the drop-out
rate due to adverse events, of both groups, will be
compared using the Fisher exact test.
2. Analysis of baseline characteristics.
3. Analysis of compliance: according to recordings in
the case report form, compliance of the two groups
will be compared.
4. Analysis of efficiency: efficiency analysis will be
based on the ITT population (all randomized
participants). Subjects without any treatment after
randomization or without any valid data of
evaluation although treated will still be included in
the analysis.
5. Analysis of primary outcome: the primary outcome
is the change in MRS compared with baseline at the
8th week (the primary time frame) and at the 4th,
20th, and 32nd week (the secondary time frame).
Analysis of covariance (for normal distributed data)
or nonparametric tests (for abnormal distributed
data) will be used to investigate whether EA is more
effective than sham EA. To detect the center effect,
a covariance model will be used. Further analysis
will be done if there is a center effect.
6. Analysis of secondary outcomes: for each group, the
mean 24-h hot flash score, MENQOL, and hor-
mones will be compared with their baseline. A t-test
or nonparametric test will be used for comparison
between groups.
7. Subgroup analysis: subgroup analyses will be
conducted according to the stage of MT (early stage
and late stage) to observe EA’s influence on MRS
and MENQOL at the 4th, 8th, 20th, and 32nd week
for participants. Analysis of covariance or
nonparametric tests will be used.
8. Analysis of blinding: the number and percentage of
subjects choosing true EA in the two selected
centers will be established. A χ2 test or
nonparametric test will be used for comparison
among groups.
9. Analysis of safety: according to adverse events listed
in the case report form, an analysis will be done
using the χ2 test or the Fisher exact test.
Quality control
To guarantee the quality of the trial, a rigorous method-
ology will be followed. Experts in different fields were in-
vited to review and revise the protocol before the trial
start. Staff from the 12 centers will participate in training
in Beijing before the trial start. A three-level monitoring
system (monitors responsible for one center, monitors re-
sponsible for all centers, and monitors responsible for the
whole trial) will be established to check the timelyperformance of the trial. Outcome assessment, completion
of case report forms, and data management will be under
strict supervision.
Discussion
In such a large scale RCT, we want to observe EA’s influ-
ence on symptoms and quality of life for MT patients. In
this trial, not only hot flashes, but also MRS, MENQOL
score, and hormone levels will be evaluated. With specific
inclusion criteria, only women experiencing MT are in-
cluded. For the placebo control, we use non-points and a
tailor-made sham needle. This needle is different from the
retractable needle usually used for sham acupuncture
[24,25]. The needle in this trial is more simply constructed
and more acceptable to Chinese people. The patent appli-
cation for the needle is in process. With the use of adhe-
sive pads and a sham electric stimulator, the appearance
of the needles and the electric stimulator look exactly alike
in the two groups, thus allowing better blinding of the
participants. Participants will be treated alone in a treat-
ment room at one time to avoid any communication be-
tween them. Though there is no completely inert placebo
acupuncture and blinding is difficult in acupuncture trials,
the placebo effect of EA can still be partially excluded in
this study.
Conclusions
In summary, the effect of EA for MT symptoms and safety
of EA will be assessed in this trial. Following a rigorous
set of controls and blinding, the placebo effect should be
partially excluded and the trial design should allow for
evaluation of the efficacy of EA for MT symptoms.
Trial status
The first participant was included on 9 June 2013. To
date, 80 participants have been recruited.
Additional file
Additional file 1: The name and statement of the 12 research
centers’ review boards are listed in the additional file.
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